Alerts will be sent to your verified email
Verify Email
GLENMARK
|
Glenmark Pharma
|
Aurobindo Pharma
|
Glaxosmithkline Phar
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
13.0 . | 865.0 . | n/a |
|
Number of ANDA's Approved By USFDA
|
25.0 . | 733.0 . | n/a |
|
Domestic Sales Growth - YoY
|
10.3 % | n/a | 7.8 % |
|
R&D as a % of Total Sales
|
7.3 % | 4.7 % | 0.07 % |
|
Financials
|
|||
|
5 yr Average ROE
|
4.18 % | 12.72 % | 40.73 % |
|
5yr average Equity Multiplier
|
1.88 | 1.46 | 1.9 |
|
5yr Average Asset Turnover Ratio
|
0.79 | 0.68 | 0.94 |
|
5yr Avg Net Profit Margin
|
2.73 % | 12.5 % | 24.91 % |
|
Price to Book
|
6.18 | 1.87 | 24.3 |
|
P/E
|
72.51 | 17.99 | 49.91 |
|
5yr Avg Cash Conversion Cycle
|
-121.67 Days | -46.37 Days | -107.65 Days |
|
Inventory Days
|
40.44 Days | 59.62 Days | 52.59 Days |
|
Days Receivable
|
36.38 Days | 30.33 Days | 22.78 Days |
|
Days Payable
|
201.37 Days | 121.28 Days | 144.46 Days |
|
5yr Average Interest Coverage Ratio
|
3.48 | 43.54 | 479.64 |
|
5yr Avg ROCE
|
16.29 % | 15.27 % | 44.44 % |
|
5yr Avg Operating Profit Margin
|
15.62 % | 19.22 % | 25.23 % |
|
5 yr average Debt to Equity
|
0.49 | 0.19 | 0.0 |
|
5yr CAGR Net Profit
|
n/a | -8.16 % | 20.96 % |
|
5yr Average Return on Assets
|
1.86 % | 8.64 % | 21.84 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
46.65 % | 51.82 % | 75.0 % |
|
Share Pledged by Promoters
|
0.0 | 17.08 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -0.01 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
9.74 % | 9.14 % | 1.11 % |
|
Glenmark Pharma
|
Aurobindo Pharma
|
Glaxosmithkline Phar
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|